Literature DB >> 10346868

Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins.

M Ono1, Y Arano, T Uehara, Y Fujioka, K Ogawa, S Namba, T Mukai, M Nakayama, H Saji.   

Abstract

Hydrazino nicotinate (HYNIC) has been shown to produce technetium-99m (99mTc)-labeled proteins and peptides of high stability with high specific activities. However, persistent localization of radioactivity was observed in nontarget tissues such as the liver and kidney after administration of [99mTc]HYNIC-labeled proteins and peptides, which compromises the diagnostic accuracy of the radiopharmaceuticals. Since lysosomes are the principal sites of intracellular catabolism of proteins and peptides, 99mTc-HYNIC-labeled galactosyl-neoglycoalbumin (NGA) was prepared using tricine as a co-ligand to investigate the fate of the radiolabel after lysosomal proteolysis in hepatocytes. When injected into mice, over 90% of the injected radioactivity was accumulated in the liver after 10 min injection. At 24 h postinjection, ca. 40% of the injected radioactivity still remained in liver lysosomes. Size-exclusion HPLC analyses of liver homogenates at 24 h postinjection showed a broad radioactivity peak ranging from molecular masses of 0.5-50 kDa. RP-HPLC analyses of liver homogenates suggested the presence of multiple radiolabeled species. However, most of the radioactivity migrated to lower molecular weight fractions on size-exclusion HPLC after treatment of the liver homogenates with sodium triphenylphosphine-3-monosulfonate (TPPMS). The TPPMS-treated liver homogenates showed a major peak at a retention time similar to that of [[99mTc](HYNIC-lysine)(tricine)(TPPMS)] on RP-HPLC. Similar results were obtained with urine and fecal samples. These findings suggested that the chemical bonding between 99mTc and HYNIC remains stable in the lysosomes and following excretion from the body. The persistent localization of radioactivity in the liver could be attributed to the slow elimination rate of the final radiometabolite, [[99mTc](HYNIC-lysine)(tricine)2], from lysosomes, and subsequent dissociation of one of the tricine co-ligands in the low pH environment of the lysosomes in the absence of excess co-ligands, followed by binding proteins present in the organelles. The findings in this study also suggested that the development of appropriate co-ligands capable of preserving stable bonding with the Tc center is essential to reduce the residence time of radioactivity in nontarget tissues after administration of [99mTc]HYNIC-labeled proteins and peptides.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10346868     DOI: 10.1021/bc980105f

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  10 in total

1.  An unexpected '4+2' [N(3)S]:[NS] rhenium(IV) complex formed upon cleavage of a Re(V) imido bond.

Authors:  Xiaoyuan Chen; Frank J Femia; John W Babich; Jon Zubieta
Journal:  Inorganica Chim Acta       Date:  2000-12-15       Impact factor: 2.545

Review 2.  Labeling biomolecules with radiorhenium: a review of the bifunctional chelators.

Authors:  Guozheng Liu; Donald J Hnatowich
Journal:  Anticancer Agents Med Chem       Date:  2007-05       Impact factor: 2.505

3.  Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: potentials for characterizing atherosclerotic plaques.

Authors:  Yuji Kuge; Nozomi Takai; Yuki Ogawa; Takashi Temma; Yan Zhao; Kantaro Nishigori; Seigo Ishino; Junko Kamihashi; Yasushi Kiyono; Masashi Shiomi; Hideo Saji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

4.  Structural requirements for in vivo detection of cell death with 99mTc-annexin V.

Authors:  Jonathan F Tait; Christina Smith; Francis G Blankenberg
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

5.  IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions.

Authors:  Signe Humle Jorgensen; Nicolas Storm; Poul Erik Hyldgaard Jensen; Henning Laursen; Per Soelberg Sorensen
Journal:  Exp Brain Res       Date:  2006-11-08       Impact factor: 1.972

6.  Biodistribution of radioiodinated adenovirus fiber protein knob domain after intravenous injection in mice.

Authors:  Vibhudutta Awasthi; George Meinken; Karen Springer; Suresh C Srivastava; Paul Freimuth
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 7.  Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases.

Authors:  Kazuma Ogawa; Atsushi Ishizaki
Journal:  Biomed Res Int       Date:  2015-05-14       Impact factor: 3.411

8.  Synthesis and preliminary evaluation of a new (99m)tc labeled substance p analogue as a potential tumor imaging agent.

Authors:  Saeed Mozaffari; Mostafa Erfani; Davood Beiki; Fariba Johari Daha; Farzad Kobarfard; Saeed Balalaie; Babak Fallahi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

9.  A 99mTc-tricine-HYNIC-labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging.

Authors:  Danial Shamshirian; Mostafa Erfani; Davood Beiki; Maliheh Hajiramazanali; Babak Fallahi
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

10.  Development and evaluation of a novel (99m)tc-labeled annexin A5 for early detection of response to chemotherapy.

Authors:  Kazuma Ogawa; Katsuichi Ohtsuki; Tomomi Shibata; Miho Aoki; Morio Nakayama; Yoji Kitamura; Masahiro Ono; Masashi Ueda; Tomoki Doue; Masahisa Onoguchi; Kazuhiro Shiba; Akira Odani
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.